Informa Australia is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Register Your Interest


Medicinal Psychedelics Conference

25 July 2024 | Crown Promenade Melbourne

BUY A PASS Register Your Interest Download Brochure

Early bird rate expires 7 June 2024


Returning in 2024, the Medicinal Psychedelics Conference is an objective platform for networking and discussion on the therapeutic potential of psychedelics compounds for medical and psychological treatments.

This conference brings together leading experts, psychiatrists, researchers, clinicians, policymakers and industry trailblazers to delve into the latest developments in Australia after one year of becoming the first country in the world to legalise the use of psychedelics to treat some mental health conditions.
By attending this conference, you will make new connections with important partners, get a real and practical picture of how the sector is evolving and participate in discussions with people who are at the coal face.

Don’t miss the opportunity to be part of this important dialogue.

Key topics include:

  • 2024 will mark a year since MDMA and Psilocybin were moved to Schedule 8 medicines in Australia – where are we now? Does the future look promising?
  • What are the perspectives and insights of practising clinicians?
  • How truly effective is psychedelics in the treatment of depression, anxiety, PTSD, and addiction?
  • Ethical and legal considerations in psychedelic therapy?
  • Psychedelics and the future of mental healthcare?
  • What are the latest regulations and policies updates?
  • Any updates on guidelines for psychiatrists prescribing psychedelics?
  • Will Australia lead the world in the new era of psychedelic medicine?


Emily Rigby

Chair, Australian Cannabis Cultivators & ISHS Cannabaceae Working Group; Director, Australian Medicinal Cannabis Association

Kelly Griffiths

Partner, Gadens

Dr Suresh Muthukumaraswamy

Associate Professor - School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand

A/Prof Vinay Lakra

Divisional Director, Mental Health, Northern Health

Justin James

Chief Executive Officer, HIF

Agnieszka Sekula

Co-Founder, Enosis Therapeutics

Dr Alexander Lim

Co-founder & Director, Zed3 Medical Group

Prof Jerome Sarris

Co-CEO, Psychae Therapeutics & Co-Director, Psychae Institute

Professor Richard Harvey

Chair, RANZCP Psychedelic-Assisted Therapy Steering Group

Prof Cathy Mihalopoulos

Head, Monash University Health Economics Group, School of Public Health and Preventive Medicine, Monash University

Prof Kylie O’Brien PhD

Chief Scientific Officer, Cannim Group

Dr Anthony Bloch

Chair, Australian Multidisciplinary Association for Psychedelic Practitioners

Prof Robyn Langham AM

Chief Medical Adviser, Health Products Regulation Group

Dr Ted Cassidy

Psychiatrist & Founder, Monarch Mental Health Group

Dr Antonio Simonelli

Consultant Psychiatrist, Co-Founder, The Good Mental Health Place

Dr Prash Puspanathan

Co-Founder, Enosis Therapeutics


8:30 am

Registration & Morning Coffee

9:05 am

Opening remarks from the Chair

Dr Prash Puspanathan, Co-Founder, Enosis Therapeutics

9:10 am

OPENING KEYNOTE | Access to MDMA and psylocibin through the Authorised Prescriber Scheme – the first six months update from the Therapeutic Goods Administration

Prof Robyn Langham AM, Chief Medical Adviser, Health Products Regulation Group

9:40 am

  • The development of the RANZCP position on psychedelics
  • The advice for psychiatrists
  • The implications of the advice

10:10 am

Microdosing psychedelics is an increasingly common community practise with users claiming a range of benefits. However, there is currently little clinical trial evidence to support many of these anecdotally claimed benefits. In this talk I will review the status of the microdosing research field, covering the limitations of the current research and where future research appears to be heading.

10:40 am

Networking Break & Morning Tea

11:10 am

Administering Psychedelic Treatments in Australia (TBC)

Dr Ted Cassidy, Psychiatrist & Founder, Monarch Mental Health Group

11:40 am

ReviveMed Ketamine Program: a targeted interdisciplinary clinical program for Veterans with TR-D, TR-PTSD, and suicidality

Dr Alexander Lim, Co-founder & Director, Zed3 Medical Group

12:10 pm

Psychedelic medicine has the potential to revolutionise mental health treatment and improve patient outcomes. Parallels between the development of the Australian medicinal cannabis industry and the emerging field of psychedelic medicine, provides opportunity to learn and fast track this new industry. Similar challenges include regulatory hurdles, patient access, research, education, industry development and stigma. Explore the lessons that can be learned from the Australian medicinal cannabis industry and applied to the development of psychedelic medicine. By learning from these lessons, the emerging field of psychedelic medicine can overcome challenges and bring much-needed therapies to those suffering from mental health conditions, establishing a robust regulatory framework that balances safety, accessibility, and industry growth.

12:40 pm

Networking Lunch

1:40 pm

  • Ayahuasca (containing DMT and harmala alkaloids) is a potent plant-based medicine with evidence of a range of therapeutic mental health effects.
  • Use of the traditional medicine has issues around biopiracy, constituent standardisation, and potential scale-up challenges.
  • We discuss the current evidence of Ayahuasca, and the creation of a scalable, purified form of DMT and harmala alkaloids for use in a range of mental health applications.

2:50 pm

  • How can therapists ensure informed consent when working with psychedelics, given the unique and often unpredictable nature of psychedelic experiences?
  • Are there specific guidelines or standards for the training and certification of therapists and healthcare professionals?
  • Are there legal and ethical considerations regarding the integration of traditional or indigenous practices?

3:35 pm

Networking Break & Afternoon Tea

4:05 pm

CLOSING KEYNOTE | Examining the advocacy and the evidence

A/Prof Vinay Lakra, Divisional Director, Mental Health, Northern Health

4:30 pm

Digital therapeutics and psychedelic treatments are gaining increasing interest as alternative treatments in mental health care. The intersection of those treatments presents itself as an interesting preposition for combination therapies. This talk provides an overview of a 3-year research examining the feasibility, benefits, and limitations of the use of VR as a psychotherapy tool in combination with psychedelics, based on studies at Swinburne University, Australia and international collaborations.

4:55 pm

  • 2024 will mark a year since MDMA and Psilocybin were moved to Schedule 8 medicines in Australia – where are we now? Does the future look promising?
  • What are the perspectives and insights of practicing clinicians?
  • What challenges and opportunities exist?

5:40 pm

Closing remarks from the Chair

5:45 pm

End of Conference & Networking Drinks


Packages Price
One Day Conference$1695$1195+GST Early Bird Rate Early Bird Rate
Virtual Pass$1595$1095+GST Early Bird Rate Early Bird Rate
Extras Price
Workshop $495+GST
Streamly Access Pass $150+GST

Early bird rate expires 7 June 2024

Sponsorship + Exhibition Opportunities

There are many opportunities for networking including social events such as networking drinks, refreshment breaks and lunches, making this not just a conference… but an all-encompassing industry “experience”.

Event sponsorship or exhibiting will allow your organisation to:

  • Build relationships with potential and existing clients
  • Generate leads from a high-level, targeted audience
  • Close sales in a more personal manner than via phone
  • Demonstrate your product in person
  • Network with the industry
  • Build brand awareness

To see what is on offer please contact:
Danielle Newman
Senior Business Development Manager
T: +61 2 9080 4318

ConnectMe + Streamly

ConnectMe • Networking enhanced

All of our events utilise a bespoke dynamic smartphone app, ConnectMe – which guarantees attendees a premium event experience. Logins are sent prior to the conference commencement allowing you to check who’s attending, schedule in meetings and catch ups, participate in live Q+A and interactive polls, and much more. ConnectMe ensures you never miss a beat prior, during and post event.


Streamly • On-Demand video vault

Streamly is a new video platform from Informa Connect – hosting hours of session recordings from our events and more. Select the Streamly add-on at the checkout to receive year round access to exclusive On-Demand session recordings from all of our related healthcare events*. Login information will be sent post event. For more information visit our Streamly page.

* Note: In a minority of cases, speakers may request their sessions to be excluded from Streamly access.

when & where

25 Jul 2024

Crown Promenade Melbourne
Power Street Reserve
8 Whiteman St
Southbank VIC 3006
+61 (03) 9292 8888

We have secured a special accommodation rate from $255* per room per night, room only, for conference attendees at the Crown Promenade for the night of 24 July 2024.

To book this rate, click here.

* Room availability and rates are subject to availability and valid until 7 days prior to the event, unless sold out prior.
Book early to avoid disappointment.


Still have a question?

General Information & Registration
Customer Service
+61 2 9080 4307

Sponsorship & Exhibition Opportunities
Danielle Newman
+61 2 9080 4318

Speaking Enquiries
Irene Amo
+61 415038730

Marketing & Media Enquiries
Hannah Hori

Get all the latest on Informa news and events

Informa Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.

Find out more